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Case presentation
A 19-year-old woman was admitted to New England Medical
Center Hospital (NEMCH) for evaluation of the nephrotic syn-
drome. The patient was in excellent health until proteinuria was
first detected 10 months earlier during the third month of her first
pregnancy. Twenty-four-hour urine protein excretion remained
in the 5 to 10 g range, and progressive pedal, hand, and pen-
orbital edema developed. During the final weeks of the preg-
nancy, hypertension was present (systolic blood pressure, 140 to
150mm Hg; diastolic blood pressure, 9Oto 96mm Hg). A healthy
infant girl was delivered approximately 3 months prior to admis-
sion. Following delivery, the edema persisted. The patient's
serum albumin concentration varied between 3.1 and 2.0 g/100
ml, serum creatinine concentration remained normal, and 24-hr
urine protein excretion varied between 4 and 15 g.
There was no history of dysuria, gross hematuria, urinary fre-
quency, flank pain, or fever. There was no history of previous
streptococcal infections or prior renal disease. She had no
known allergies and was using no medications.
On admission to NEMCH, the patient was in no distress. The
physical examination revealed the following: blood pressure,
132/80 mm Hg; pulse, 60/mm without postural change; respira-
tions, 12/mm; and temperature, 370 C; the head, eyes (including
optic fundi), ears, nose, and throat were unremarkable; the chest
was clear to auscultation and percussion. The cardiac examina-
tion and peripheral pulses were normal. The abdominal, pelvic,
and rectal examinations were unremarkable. Presacral edema
and pitting edema (2+) from the knees to the ankles were pres-
ent. The neurologic examination was within normal limits. There
were no skin rashes, petechiae, or eruptions present. Laboratory
findings disclosed the following data: hemoglobin, 14.5 g/lOO ml;
white blood cell count, 10,400 mm3 with a normal differential;
platelet count, 265,000 mm3; serum creatinine, 0.9 mg; blood
urea nitrogen, 11 mg/100 ml; serum sodium, 141 mEq; serum po-
tassium, 4.3 mEq; serum chloride, 107 mEq; serum bicarbonate,
26 mEq/liter; total serum protein, 5.5 g; serum albumin, 3 g;
serum cholesterol, 315 mg; serum calcium, 9.1 mg; serum phos-
phorus, 4.4 mg; and serum uric acid, 5.3 mgIlOO ml. Liver en-
zymes were normal. Fasting and 2-hr postprandial blood sugar
concentrations were normal. Results of chest x-ray and elec-
trocardiogram were unremarkable. Results of urinalysis revealed
the following: specific gravity, 1.023; pH, 6; protein 4+; no glu-
cose; white blood cells, 10 to 15/high power field (HPF); red
blood cells, 4 to 5/HPF; no casts were present. Two urine cul-
tures revealed less than 30,000 colonies of staph species and dip-
theroids. The 24-hr urine protein excretion was 4.4 g. An i.v.
urogram revealed kidneys of normal size with prompt bilateral
function and no evidence of obstruction. An antinuclear anti-
body test was negative, and serologic tests for rheumatoid fac-
tor, syphilis, and streptozyme level were negative. The total he-
molytic complement activity was 195 U (normal, 150 to 250 U)
and the complement 3 (C3) concentration was 0.73 mg/mI (nor-
mal, 0.87 to 2.2 mg/mI).
Results of an open renal biopsy revealed membranous ne-
phropathy (Fig. 1).
The patient was entered into the interhospital Study of Adult
Idiopathic Nephrotic Syndrome (120 mg/day of prednisone ver-
sus placebo). The patient began her assigned "medication"
(which later was disclosed to be placebo) 2 months after admis-
sion and continued for 8 weeks. She developed mild-to-moderate
acne and gained weight. At the end of the treatment period, the
serum creatinine concentration was unchanged at 0.8 mg/lOO ml,
and the serum albumin concentration remained at 2.8 g/100 ml;
the 24-hr urine protein excretion was 15 g. Since there was no
evidence of any response to therapy, the medication was discon-
tinued in accordance with the experimental protocol.
Presently, approximately 3.5 years after biopsy, the patient is
in the second trimester of her second pregnancy and doing well
clinically although she continues to have heavy proteinuria and
significant hypoalbuminemia. Her renal function, however, as
measured by her serum creatinine concentration of 0.6 mg/100 ml,
remains normal and she is normotensive.
Discussion
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DR. J. S. CAMERON: This woman presented at
age 19 approximately 4 years ago. She had protein-
uria in the nephrotic range then and since, but ede-
ma only during her pregnancy. One of the questions
that arises immediately is, How far can one work up
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such a patient in the middle of pregnancy? Clearly,
there was no great problem for this patient because
she went through to a full-term normal delivery.
One can, of course, do a needle renal biopsy during
pregnancy in the sitting position if necessary. The
problem of localizing the kidneys is increased, how-
ever, because of the radiation dose to the fetus.
Like the physicians treating this patient, we tend
not to biopsy during pregnancy, but to wait for de-
livery and then do the full investigation. One of the
other questions that arises at this point is, How long
had she had proteinuria. As with so many patients
with glomerular disease, the answer is that we don't
know. All we can say is that the condition was
found at this point, and we can suspect rather
strongly that it preceded her pregnancy and was not
precipitated by it. First pregnancy is one of the oc-
casions, like induction into the Armed Forces or in-
surance examinations, when we discover protein-
uria. When we talk about follow-up and we show
long-term survival statistics, we have to remember
that these are data all related to the apparent clini-
cal onset of the disease. The biological onset of the
diseaseis something we never know.
A renal biopsy was done early in the patient's
workup and showed according to the report typical
optical and immunofluorescent findings of mem-
branous nephropathy. I thought perhaps we might
pause and review this biopsy first.
DR. S. ROSEN (Beth Israel Hospital, Boston): The
renal biopsy, obtained through an open surgical
procedure, was an excellent specimen containing
much renal cortex (Fig. 1). The glomerular tufts had
apparent diffuse thickening of peripheral capillary
walls and mild mesangial hypercellularity accom-
panied by matrical increase. In scattered glomeruli
the process was more severe, and segmental capil-
lary lumenal obliteration, adhesions, and fibrocellu-
lar crescents were observed. A typical spike pattern
of the glomerular capillary wall was noted in silver
methenamine preparations. Focal interstitial fibro-
sis, tubular atrophy, and chronic inflammation were
seen; the vessels were unremarkable. Immuno-
fluorescent findings were that of a glomerular 3 +
IgG coarse peripheral granular pattern with a slight-
ly less intense B1C and a trace to 1 + 1gM deposition
in a similar distrubution. The l epon sections
stained with methylene blue-azure IT-basic fuschin
clearly delineated glomerular capillary subepithelial
deposits. Electron microscopic studies disclosed
diffuse subepithelial electron-dense deposits and
extensive foot process fusion; no subendothelial or
mesangial deposits were recognized. Mesangial hy-
percellularity and matrical increase, as seen by light
microscopy, were also noted. In conclusion, this
pattern is that of membranous nephropathy with
mild proliferation and focal sclerosis.
DR. J. S. CAMERON: This biopsy showed mesang-
ial hypercellularity and segmental sclerosing le-
sions. I think most people now would accept both
these features Ill] as complications or associated
features of membranous nephropathy, the latter es-
pecially in advanced cases. On the other hand, the
combination of these observations makes one won-
der, based on the findings of optical microscopy
alone, about systemic lupus erythematosus (SLE).
I think perhaps we might usefully discuss at this
point what is for or against SLE in this particular
biopsy and how to tell the difference between an
SLE membranous biopsy and an idiopathic one.
Does this patient have SLE? The obvious answer
is to do the appropriate tests: look for antibodies to
double-stranded native DNA by either the Fan Test
or the more recently introduced Crithidia Luciliae
kinetoplast test, which is cheap, quick, and easy as
opposed to the Farr Test. Finally, our decision as to
whether or not a patient with no obvious clinical
stigmata of SLE can be called SLE depends on this
information. I assume that the tests in this patient
were and remain negative, and that she does not
have SLE. Usually, even in a patient with SLE
membranous nephropathy, there are some suben-
dothelial or mesangial deposits. Pure membranous
nephropathy, however, can occur in SLE without
any mesangial or subendothelial deposits. Can im-
munofluorescence help us to distinguish SLE mem-
branous from idiopathic membranous nephropathy?
The answer is yes, but only to a limited extent.
Most of us expect to find a "full house" of immuno-
globulins—IgG, 1gM, and IgA—together with early
components of complement, such as Clq and C4 112],
which were not looked for in this particular biopsy.
Their absence makes one suspicious that the patient
does not have SLE. This isn't an invariable rule,
and certainly we have some patients who seem to
have idiopathic membranous nephropathy with a
"full house" of immunoglobulins—about 20-30% of
our patients. Of 42 of our patients with idiopathic
membranous nephropathy, all biopsies showed
IgG, and 75% showed C3, as everyone reports.
About 30% of patients had IgA, or 1gM, or both;
about 30% had fibrin deposition; and 20% had early
complement components. Thus, if the kidney
biopsy in a patient who appears to have idiopathic
membranous nephropathy shows all complement
components and immunoglobulins, it raises the
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Fig. 1. Renal biopsy. (A) In this silver methenamine preparation, segmental glomerular sclerosis, mild mesangial hypercellularity, and a
focal basement membrane spike pattern (arrow) can be observed (x570). (B) The subepithelial deposits are distinct in the stained 1 p.
epon section (x 1068). (C) Subepithelial electron dense deposits, basement membrane projections, and extensive foot fusion are noted
in this electron micrograph (x3204).
question of whether the patient has SLE. IgA was
absent in the patient presented today.
I assume that this patient was screened for Aus-
tralian antigenemia [3], and that she is not C2 defi-
cient [4], which are two clinical associations one
can detect. I am just mentioning these because later
on we will be talking about the circumstances asso-
ciated with membranous nephropathy. Our own se-
ries of membranous nephropathy patients is now
just around one hundred patients: two-thirds male
and one-third female. A woman 19 years old is a
prime subject for SLE. We should not forget that
idiopathic membranous nephropathy with no tests
positive for SLE may evolve into florid clinical and
immunological SLE [5, 6]. We had two such cases,
and I think this possibility justifies doing tests for
SLE and complement concentrations not just once,
but from time to time.
We should also ask whether this biopsy falls into
the group described by Burkholder, Hyman, and
Krueger [71 as mixed membranous and proliferative
glomerulonephritis, type III. The study described a
small group of patients with mesangial proliferation,
sometimes some segmental accentuation of the pro-
liferation, and not only epimembranous deposits
but also subendothelial and mesangial deposits.
Since we have seen the electron microscopy, we
can say that the present patient doesn't fit into this
s . -. .'r.3"S' •I% fl? !Ø
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category. Had we not had that available to us, I
think we might have just wondered whether she was
one of this group of patients. Because they have
been little discussed, I thought I would briefly men-
tion our experience with ten such patients. All their
tests for SLE were negative, all their complement
concentrations were normal, and they did not have
the complement abnormalities we associate with
mesangiocapillary glomerulonephritis (MCGN).
Rather than consider this disorder an extra variety
of MCGN or membranoproliferative glomerulone-
phritis (MPGN), we regard it as a separate variety:
'glomerulonephritis with deposits at multiple
sites." Both of the well-known forms of MCGN, of
course, may show some subepithelial deposits, but
these are rather infrequent. Nobody talks about
these patients, and they are excluded from pub-
lished papers. Some regard them as an atypical
form of membranous nephropathy.
Could we have diagnosed membranous nephrop-
athy on clinical grounds? I don't think there are any
specific characteristics in the differential diagnosis
of nephrotic patients that will allow you to pick out
membranous patients from the others. Patients with
membranous nephropathy are more often male,
usually have microscopic hematuria as this patient
did, and even in mild cases differential protein
clearances are usually nonselective. Renal function
and blood pressure may both be normal or abnor-
mal. Recently, two attempts to predict histologic
data on clinical grounds have been published. One
was in adults using a sequential Bayesian analysis
[8], and the other was in children using discriminant
function analysis [9]. Both suggested that you could
progress a long way clinically toward discriminating
among different patients using these analyses on all
the data available. I think that while this may be
possible in children, our current attitude is that all
adult nephrotics should have renal biopsy as part of
their evaluation, if only so that we can give the pa-
tient or relatives a more accurate prognosis apart
from the question of treatment. I would be inter-
ested in learning your views about renal biopsy in
nephrotic patients.
The patient under discussion was entered in the
collaborative Study of Adult Idiopathic Nephrotic
Syndrome [10], and we will hear more about this
later. I gather that despite developing acne and
gaining weight, she was receiving a placebo! Four
years since she was first documented as having pro-
teinuria, her renal function remains within normal
limits, and profuse proteinuria without edema per-
sists. Now she is pregnant again with delivery ex-
pected in a few months, and I think we might pause
to consider the management of the nephrotic patient
who becomes pregnant. During the second trimes-
ter, the patient was still normotensive without ede-
ma, but had urinary protein excretion of 3.2 g/24 hr.
Her serum creatinine concentration was only 0.6
mg/100 ml, which I take as an indication that she
had achieved the supranormal glomerular filtration
rate (GFR) and creatinine clearance that one would
expect as part of the normal second trimester of
pregnancy. Her urine is being cultured every month
as a routine appropriately. There are few data on
this. In one study, however, of 31 pregnancies in 19
patients with the nephrotic syndrome [11], 11 were
complicated by bacteriuria, or overt clinical infec-
tions, or both, which is of course a much higher fig-
ure than the 7% or so that you expect in normal
pregnant women. I am frankly not very worried
about a patient like this in pregnancy [11, 12], so
long as the patient has normal renal function and
above all normal blood pressure. I think previous
reports in the literature on pregnancy and renal dis-
ease have not clearly distinguished the different ef-
fects of different renal diseases and the effects of
hypertension and diminished renal function on
pregnancy. In fact, renal function isn't necessary to
become pregnant and carry to term. We (and oth-
ers) have had a patient on dialysis who delivered a
normal child [13]. The dangerous thing is hyper-
tension, especially if it is present before the preg-
nancy begins and above all ilit is accompanied, as it
was fortunately not in the case of this patient, by
reduced renal function. Patients with GFR of
around 40 mi/mm and fairly vicious hypertension
are, to my mind, about the limit at which one can
expect to get a pregnancy through to an early con-
clusion with a live baby. In patients with mem-
branous nephropathy, our own experience and that
in the literature [11, 13] is very good. Very few pa-
tients have aborted or developed severe hyper-
tension and lost the baby, and I would hope that this
patient's second pregnancy will be as successful as
the first one was. There is an association between
hypoalbuminemia and small babies [11], and since
her serum albumin concentration is low (3 g/100
ml), we can expect her baby to be a little smaller
than normal. I don't think this indicates dysmatu-
rity or that all of these women are having their
babies early; I suspect that it simply reflects the fact
that the infants are slightly protein-malnourished,
although there is no good evidence for this.
I think this patient will go to term and have a nor-
mal baby because she has been "road-tested" once
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already and both her renal function and blood pres-
sure are normal. We will discuss her long-term out-
look when we discuss membranous nephropathy in
general.
Are there any questions so far?
DR. J. T. HARRINGTON: Of interest is your com-
ment about the long time-lag between the onset of
apparently idiopathic membranous nephropathy
and the subsequent development of SLE in some
patients. Could you be more specific?
DR. J. S. CAMERON: Well, one of our patients
took between 2 and 3 years, and Libit et al [5] docu-
ment cases of!, 3, and 5 years. Simenhoff and Mer-
ril's [6] patients took 5 months and 7 years. One of
these was a C2 deficient patient, whose course they
had earlier published as an association between C2
deficiency and membranous nephropathy. Of
course, if the possibility of SLE had not been inves-
tigated adequately, some of these patients could
have had SLE all the time. I have only mentioned
patients in whom it was carefully assessed at the
beginning of their illness.
DR. J. J. COHEN: Dr. Coggins, does your recent
Study of Adult Idiopathic Nephrotic Syndrome 1101
indicate whether or not patients with membranous
nephropathy can continue longer than 5 years and
then develop SLE.
DR. C. H. COGGINS (Massachusetts General
Hospital, Boston): There were three patients in the
study in whom pathologic reports indicated SLE
from the outset, but the serologic tests were nega-
tive. Within a fairly short period of time in each
case the serologic tests became positive. The pa-
tients did not, however, have membranous ne-
phropathy; they had "mixed deposit disease."
DR. J. S. CAMERON: We looked very hard at the
pathologic reports of a patient with atypical mem-
branous nephropathy who subsequently developed
SLE. She had only subepithelial deposits on the
plastic-embedded material. We looked carefully at
the mesangium and the subendothelial space, and
no deposits were seen initially. Our pathologist
commented on the great irregularity in size and
number of the deposits around the different capil-
lary loops in our patients, compared with the mo-
notonous regularity of the typical idiopathic mem-
branous biopsy. He suspected SLE, and he was lat-
er proven to be right.
Does anyone feel that the patient under dis-
cussion should have been biopsied in pregnancy?
DR. J. T. HARRINGTON: We were not caring for
this patient at the time of her first pregnancy, but we
have never biopsied a patient during pregnancy. In
answer to your earlier question about biopsying
adults with nephrotic syndrome, I believe most
nephrologists in the United States prefer to biopsy
virtually all adult patients with nephrotic syndrome,
except those with diabetes.
DR. J. S. CAMERON: Perhaps I might add what we
do in patients with diabetes. We require some clini-
cal clue, such as the absence of retinopathy or the
presence of persistent microscopic hematuria, that
suggests something else besides the presence of dia-
betic nephropathy. Undoubtedly, if you do biopsy
these suspicious patients with diabetes, then you
find a good portion of them do not have diabetic
nephropathy. Wass et al [14] think that most units
are biopsying too few patients with diabetic ne-
phropathy. There is no real answer to this. Cer-
tainly a lot of clinically unnecessary biopsies would
be performed if every diabetic with proteinuria
were biopsied.
Churg has found a very high incidence of diabetes
in his series of patients with membranous nephropa-
thy [15]. In contrast, we only have 1 patient with
clinical diabetes in 100 patients with membranous
nephropathy. Clearly, the New York population
differs in this respect from the London population,
or the selection of patients differs markedly.
DR. C. H. COGGINS: That incidence would, of
course, depend heavily on whether you decide to
biopsy patients with diabetes. An abnormal glucose
tolerance test eliminates a patient from our study. I
might add that in trying to decide whether to biopsy
patients with diabetes we also use the absence of
retinopathy as a clinical clue. Recently, a patient in
our hospital, who had no retinopathy detectable by
fluorescein study, had a nephrectomy (before trans-
plantation) and had clear histologic findings of dia-
betic nephropathy.
DR. J. S. CAMERON: Rather than discussing in de-
tail the histopathology of membranous nephropa-
thy, which is interesting but very well-documented
116], I want to talk more about what we do and do
not know about the immunopathogenesis of this dis-
ease. Membranous nephropathy can be found in a
variety of circumstances, some of which suggest
that like other forms of glomerulonephritis it may be
a consequence of glomerular deposition of circulat-
ing soluble complexes. Until recently this seemed
to be the likely explanation for the pathogenesis of
this condition. There are two salient features in
membranous nephropathy, however, that require
an explanation. First, most investigations fail to
find, by the various techniques for detecting circu-
lating immune complexes, material in many patients
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with membranous nephropathy [17, 18, 19]. The
highest percentage I have been able to find is in Bor-
der's [20] series from the collaborative Study of
Adult Idiopathic Nephrotic Syndrome in which, by
one method at least out of the three they employed,
almost half the patients with membranous nephrop-
athy were shown to have complex-like material.
Most people score less than 20%, and some zero
[17]. Second, despite the glomerular deposition of
immunoglobulins and complement components, as
in other forms of nephritis, there is a striking ab-
sence of obvious glomerular proliferation in the ma-
jority of patients.
The relationship of membranous nephropathy to
possible immune complex deposition is a fascinat-
ing one. First, we must consider Dixon and Ger-
muth's work. It was demonstrated that a pattern re-
markably like that of membranous nephropathy
could be induced in rabbits given chronic serum
sickness by repeated daily injections of a foreign
protein using a constant low-dosage schedule (2.5
mg/day) [21, 22] Germuth showed further that the
deposition of complexes in the peripheral capillaries
giving a membranous-like pattern was associated
with the presence in the circulation of smaller im-
mune complexes. In contrast, rabbits given foreign
protein according to different schedules showed
deposition of larger complexes principally in the
mesangium. You will note that I have avoided
saying that these complexes were necessarily being
deposited in the glomeruli; but they were in the cir-
culation, and Germuth presumed like many other
investigators that this was indeed the case. Further
study suggests that the membranous pattern was as-
sociated with small quantities of complexes in the
circulation [22]. Kuriyama [23], working with oval-
bumin-induced nephritis in rabbits, and Koyama et
al [24], who injected performed complexes of bo-
vine serum albumin into mice, suggested that the
animals, which produced principally low avidity
antibody, showed peripheral membranous-like dep-
osition of complexes rather than mesangial deposi-
tion.
One can postulate, then, that human glomerulo-
nephritis might arise from the presence in the circu-
lation of small amounts of complexes formed from
low avidity antibody, and that this explains the rela-
tive difficulty of detecting immune complexes in this
disorder. This contrasts with mesangiocapillary or
postinfectious glomerulonephritis and SLE, in
which complexes are easily found in large amounts
in the majority of patients.
Could it be that membranous nephropathy is not
the result of the deposition of circulating complexes
at all, and that this explains why we cannot find
them? I would now like to review some work done
during the past few years which supports the idea
that complexes may form by combination of anti-
body and antigen in situ within the glomerulus, and
that this may be one mechanism—perhaps the prin-
cipal mechanism—by which membranous nephrop-
athy arises.
For a time after the work of Dixon and Germuth,
we became used to thinking that there were funda-
mentally two contrasting varieties of nephritis (Fig.
2). One variety was that in which deposition of anti-
body against glomerular antigens induced the in-
flammation; the other variety was that due to the
deposition in the glomerular capillary walls of im-
mune complexes formed in the circulation, and
again inflammation was induced. What we are talk-
ing about now is the possibility that a new antigen
"planted" either in the glomerular capillary wall or
the mesangium might combine with circulating anti-
body to induce inflammation. In retrospect, of
course, the autologous phase of antiglomerular
basement membrane antibody nephritis is an ex-
ample of this: The heterologous antibody fixes to
the glomerular basement membrane, and after sev-
eral days autologous antibody to this foreign protein
(in this case heterologous IgG) forms, and it is dur-
ing the fixation of this autologous antibody that the
inflammation and renal damage takes place.
Some of the earlier observations in this field were
those of Mauer [25]. He localized aggregated immu-
noglobulin in the mesangium in experimental ani-
mals and then injected an antibody directed against
this immunoglobulin. The result was a brisk nephri-
tis. More recently, another experiment was report-
ed by Golbus and Wilson [26] in which Con-
canavalin A was attached to the glomeruli, an anti-
body against it injected, fixed, and again a nephritis
was produced.
It has become clear that in another of the hal-
lowed models of presumed soluble complex dis-
ease—acute serum sickness in rabbits—one of the
earliest events that can be detected in the glomeru-
lus is the deposition of the foreign protein without
any antibody or complement. After a couple of days
as the antibody against the foreign protein appears
in the circulation, it then appears in the glomeruli.
Finally after another 2 or 3 days, immune elimina-
tion of the circulating foreign antigen by the anti-
body occurs with extensive deposition of com-
plexes. It is quite possible, therefore, in even an
old-fashioned disease such as acute serum sickness
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(which has been with us since Von Pirquet in 1908)
that the renal injury is partly mediated through in
situ immune complex formation.
The first suggestion (so far as I am aware) that
human membranous nephropathy might result from
in situ formation of complexes in the capillary wall
came from Evans in 1974 [27]. He suggested that
differential filtration of various antigens and anti-
bodies through the capillary wall, to produce an
antibody-antigen ratio in the subepithelial space
suitable for complex formation, might account for
the formation of deposits at this site. He further
pointed out that once deposited such complexes
might be in equilibrium with the antigen and anti-
body in the circulation. Although more recent work
on other determinants of molecular penetration into
the glomerular capillary wall besides molecular
size, in particular charge [28], has rendered his de-
tailed arguments obsolete, the idea remains a fruit-
ful one.
This brings us to a discussion of the model usual-
ly thought to resemble human membranous glomer-
ulonephropathy most closely— Heymann nephritis.
In brief, the original descriptions of this model by
Glassock et al [29] showed that when rats were giv-
en injections of isologous kidney, a nephritogenic
antigen could be found in the renal tubular brush
border, called renal tubular epithelial (RTE) anti-
gen. When this was prepared crudely and injected,
antibody was induced in the host rat, and a chronic
membranous nephropathy appeared with the gb-
merular deposits containing RTE antigen. The anti-
gen was detected in a particular fraction of the tu-
bule preparation called FX 1A, and hence it is re-
ferred to as FX 1A in many publications. This
fraction contains several antigens, and most work
has been done with relatively crude preparations.
Initially it was assumed that this disease resulted
from the formation of FX IA-antiFX 1A immune
complexes in the circulation and their subsequent
deposition within the kidney. Barabas, Nagi, and
Lannigan [30], however, showed that a single injec-
tion of antiFX 1A antibody could also lead to pro-
longed proteinuria. They postulated that the FX 1A
released from tubules following the injection led to
the formation of complexes with the injected anti-
body; the complexes thus formed then deposited in
the glomeruli. This form of the disease is usually
referred to as "passive" Heymann nephritis [31].
Van Es et al [32] showed later that the chronic pro-
teinuria that followed the single injection of rabbit
antiFX 1A depended upon secondary autologous
antibody directed against the heterobogous rabbit
antiFX lA antibody present in the glomeruli, the
immune complex thus acting as a "planted" anti-
gen.
Even more fascinating, it has been shown that the
gbomerular basement membrance contains antigens
that cross-react with antiFX IA, and that formation
of complexes within the glomerular wall follows
within seconds of injection of the antiFX 1A anti-
body [33, 34]. The crucial experiments involved in
vivo perfusion of the isolated kidney with antiFX
IA antibodies both from the circulation and eluted
from the kidneys of rabbits with nephritis, both of
which fixed, and FX 1A-antiFX 1A complexes,
which did not. This work has been confirmed re-
cently by Steinmuller et al [35] using an in vitro iso-
lated perfused kidney system.
All of this may be relevant to human membranous
nephropathy, although the extent to which in situ
complex formation contributes is unknown. It is
quite possible that both mechanisms—deposition of
complexes formed in the circulation and in situ
complex formation—are important. In other forms
of glomerubonephritis, deposition of soluble com-
plexes may predominate, but membranous ne-
phropathy may be a disease in which the majority of
the immune material is formed within the sub-
epithelial space. This could explain why one cannot
find complexes in the circulation in the majority of
patients, and might explain the failure of mem-
branous nephropathy to transmit to grafted kid-
neys, unlike other forms of gbomerulonephritis such
as MCGN or mesangial IgA disease [36]. In passing,
it is also interesting to remember that SLE, rather
surprisingly, does not transmit to grafted kidneys.
A priori, this is one of the forms of glomerulone-
phritis that one would think might transmit with reg-
ularity. A suggestion from Izui, Lambert, and Mies-
cher [37], however, is relevant here. These workers
proposed that DNA might bind to basement mem-
brane collagen and then react in situ with circulating
antiDNA antibody; this might then allow other
complexes in the circulation access to the capillary
wall from which they were otherwise excluded.
Whether there are antiDNA-DNA complexes in the
circulation at all is the subject of present debate [38,
39].
One can begin to play with these new ideas to
speculate on what determines the initiation and pro-
gression of nephritis. Certainly, events that might
modify the gbomerular capillary wall permeability
[29] become crucial if antigen and antibody are to
gain access to the subepithelial space. Low-affinity
antibody could certainly exist in the circulation
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Table 1. Antigens and circumstances reported to be associated with membranous nephropathy
Intrinsic antigens Extrinsic antigens Debatable associations
DNA Hepatitis B Renal venous thrombosis
Renal tubular epithelial Tuberculosis pallidum Diabetes
Carcinoembryonic Filarial Rheumatoid arthritis
Other tumor Mercury and mercurials Sjogren's syndrome
Thyroglobulin Gold
Penicillamine
Tridione
Sarcoidosis
Tuberculosis
alongside free antigen and form complexes in the
capillary wall while there were few or none in the
circulation, as suggested by Evans [28]. It may be
that only some special sorts of antigen can do this,
but the variety of circumstances in which mem-
branous nephropathy may be found suggests that
many antigens must be capable of this. This specu-
lation may lead us not to chase complexes in the
circulation, but to go to the kidney to study the ac-
tual site where the damage is taking place.
Turning back to human membranous glomerulo-
pathy, Table 1 shows some antigens that are impli-
cated in the human disease. The most interesting in
view of the discussion today, is the possibility that
some patients may have membranous nephropathy
arising from immune complexes with RTE as the
antigen. Naruse et a! [40, 411 first discussed this
possibility, but we [421 were unable to confirm this
either in idiopathic or in drug-induced membranous
nephropathy using antisera to a slightly different
nephrogenic antigen extracted from human urine. I
believe other studies have also failed to confirm this
interesting finding although Ozawa et al [43] sug-
gested that, as one might expect, RTE was involved
in the membranous nephropathy secondary to renal
venous thrombosis. Costanza et al [44] described a
patient in whom carcinoembryonic antigen (CEA)
appeared to be the antigen involved. We [45] and
others have been unable to confirm this association,
which is surprising since it is now 5 years since that
paper was published, and a number of patients have
been studied using several different antigenic de-
terminants of the CEA to prepare the antisera. Also
with reference to Table 1, it should be pointed out
that membranous nephropathy may be associated
with Hodgkin's disease, as well as the more usual
"minimal change" pattern.
The extrinsic antigens are also listed in Table 1.
There are a number of infectious agents and drugs
that are particularly associated with membranous
nephropathy. The patients with this variety of mem-
branous nephropathy are particularly important be-
cause they teach us two things: First, the continued
deposition of something in the glomerulus is neces-
sary for the continuing disease, because if you take
away the drug these patients almost invariably get
better although it can take 1 or 2 years. Second,
there is some mechansim by which the glomerulus
can remove the subepithelial or intramembranous
deposits; the nature of this is obscure.
Finally, some more general and debatable associ-
ations of membranous nephropathy are shown in
Table 1. We have already discussed the possible as-
sociation with diabetes mellitus. I will end the dis-
cussion of the possible associations of membranous
nephropathy by simply stating that my own prej-
udice is that renal venous thrombosis is in all proba-
bility secondary to the glomerular disease in every
case.
As I mentioned earlier, I do not wish to discuss
the histopathologic changes in detail. They have
been well described by Ehrenreich and Churg [15]
and by Baridty et al [46]. I will only make three
points: First, oil immersion on immunofluorescent
material may be necessary to demonstrate the finest
granular deposits in stage 1 membranous nephropa-
thy, and one may be tempted to diagnose linear im-
munofluorescent studies erroneously unless immer-
sion is used. Second, the classical "spikes" of stage
2 membranous nephropathy may not be present in
early stage 1 cases. To differentiate these from
minimal change" lesions, the capillary walls cut
obliquely are more helpful, because if silver prepa-
rations under the oil immersion are used one can
see a bubbly" appearance of deposits cut through
horizontally. Third, after clinical resolution of mem-
branous nephropathy and a normal biopsy appear-
ance on optical microscopy, electron microscopy
may still reveal lucent areas within the apparently
normal basement membrane, which we believe rep-
resent the sites of leached-out deposits. Gartner et
a! [47], who described this appearance, have called
this stage 5 membranous nephropathy. It is already
clear from the lack of correlation between renal
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function and renal biopsy grading [16] (Fig. 2) that
stages 1 through 4 do not represent progressively
worse manifestations of the disease, although 1
through 3 may represent a histologic evolution. In
general, GFR does not correlate well with glomeru-
lar changes in glomerular diseases, but correlates
much better with interstitial and tubular changes.
Perhaps we can finish by considering the long
term outlook for patients with membranous ne-
phropathy. Figure 3 shows the actuarial survival for
all the published series of membranous nephropa-
thy up to 1976, including our own data [48]. You can
see that by and large this is a slowly progressive
disease with renal failure and other causes of death
coming in 3 to 5 years from onset. Figure 4 summa-
rizes data from all the patients with membranous
nephropathy whom we biopsied more than 10 years
ago. All these 33 patients had at least 10 years of
potential follow-up. These data are percentages of
those analyzed at that particular point, not actuari-
ally calculated figures. The proportion of patients in
remission apparently decreases as we lose a few pa-
tients from follow-up around the decade mark. I
suspect that the proportion in remission would be
around 40% at 10 to 15 years. We lost mainly pa-
tients who were fit and well, which is what always
happens. Another point I particularly want to make
is that there are no renal deaths in our series until
after 3 years, and that any study with an end-point
based on terminal renal failure is going to have to
run at least 5 or 10 years. Finally, there are quite
large numbers of nonrenal deaths, particularly from
cardiovascular disease.
Figure 5 is my summary of what probably hap-
pens to patients with membranous nephropathy
from all the literature and from our own series. By
15 years, there are probably very few patients with
active disease and none with a continuing nephrotic
syndrome. From our own data, most of the patients
who go into renal failure appear to suffer a per-
sisting nephrotic syndrome and transfer from this
category to that of renal death.
Recently, Hopper, Trew, and Biava [49] have
suggested that male patients do much worse than
female patients with membranous nephropathy
when renal failure is considered. This has not been
the case in our own series of 94 patients. Of 59 men,
8 have died (or required substitution therapy), and
only 3 of these deaths (5%) have been from renal
failure as against 8 deaths among 35 women, 4 of
them (12%) from renal failure. The mean follow-up
in our series is similar to Hopper's, and the mean
ages almost identical. In his series, one-third of
male patients had gone into terminal renal failure
before 7 years had passed. Even excluding the few
children in our series, the difference persists.
1oo
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Fig. 3. Actuarial survival of patients with membranous nephrop-
athy, calculated from series published up to 1976. Deaths and the
requirement for dialysis or transplantation have been included as
"deaths". Deaths from 'nonrena]" causes (e.g., myocardial in-
farction) have been included. All series predominantly or entire-
ly of adult patients, except data taken from Ref. 51 represented
by solid triangle (A). Data taken from Ref. 48 represented by
solid circle (•).
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Fig. 2. Different mechanisms for the generation of injurious im-
mune complex formation in glomerulonephritis. (I) anti-
glomerular basement membrane antibody nephritis, (2) deposi-
tion of circulating immune complexes, (3) in situ complex forma-
tion, (4) secondary autologous antibody deposition. (See text for
explanation.)
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An interesting observation is that younger pa-
tients do better than older patients. Table 2 shows
an analysis of data on adults and children from the
literature [48]. This is true even though the propor-
tion of nephrotic patients is about the same in either
group. The percentage in renal failure at about 5
years is only 4% in the children, but 20% in the
adults. Also the remission rate (that is to say the
complete absence of proteinuria or clinical signs of
renal disease) is almost 50% in the children, but
much lower in the adults. The proportion of remis-
sions might be dependent on how many patients
were treated if treatment works, but in crude figures
35% of the children and 8% of the adults went into
remission without any treatment whatsoever except
diuretics. In our own series (see Table 3), about
25% of the patients went into remission without any
treatment. You can compare these data with the
more extensive data from Ehrenreich et al [501,
which caused such a stir because they suggested an
effect of corticosteroids on membranous nephropa-
thy (see Table 3). As you can see in our data, out of
26 patients who received nothing at all 8 went into
remission, which is approximately 25% (see Table
3). We, certainly, have not been impressed with the
idea that steroids make any difference at all to these
patients and we have stopped treating our patients
with membranous nephropathy with corticoste-
roids.
Using current measurement of GFR or creatinine
clearance as the end-point for a trial of therapy,
many years will be necessary to demonstrate an ef-
fect if one is present. Any tool we have is going to
be a blunt instrument in under 5 years. This must be
remembered when we examine the essentially nega-
tive results that have emerged from the trials car-
ried out so far (see Table 4). Most of these trials
lasted for only a year or two, and in several the
numbers were small; in the Medical Research
Council trial, neither the dosage nor the duration of
treatment was standardized.
At this point, we must raise the data of the collab-
orative Study of Adult Idiopathic Nephrotic Syn-
drome [10]. With Dr. Coggins present, I will only
say that at first I viewed these data with great skep-
ticism, but the randomization and analysis seem to
have been impeccably performed and appear to
show an effect of corticosteroids in delaying renal
failure and diminishing proteinuria in adult patients
In remission with membranous nephropathy. I am reminded of
the epigraph of Toulmin: "A man demonstrates his
Persisting rationality . . . by the manner in which, and thedisease
occasions on which he changes [his] ideas, proce-
dures and concepts" (italics added) [54]. I hope that
Renal deaths I will be able to demonstrate my rationality by
changing my belief on the absence of specific treat-
Nonrenal ment for membranous nephropathy, but we need
deaths more data and must take steps to generate them.
Questions and Answers
DR. J. T. HARRINGTON: Dr. Coggins, will you
lead off by briefly summarizing and commenting on
the results of the Study of Adult Idiopathic Ne-
phrotic Syndrome?
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Fig. 5. A synthesis of the probable long-term outcome of adult
patients with membranous nephropathy. An increase in the pro-
portion of patients with minor. proteinuria at apparent onset (i.e.,
clinical discovery), for example by a change in biopsy policy in
isolated proteinuria, would improve the prognosis of the group.
A diagram for children would probably be similar, but the pro-
portion with persisting nephrotic syndrome and renal death
would be smaller. (Derived from data in Figs. 3 and 4.)
Patients
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Fig. 4. The status at last follow-up, of 33 patients with mem-
branous nephropathy biopsied before 1968. The percentage of
patients in each follow-up category is indicated at left, and the
number of patients available for analysis (including all those then
or previously listed as dead or on dialysis) is indicated at top.
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Table 2. Comparison of outcome in adult and childhood onset patients with membranous nephropathy'
NSb
F/U
>5 yr
Deaths
in CRF
Remissions
(Treatment)
Remissions
(No treatment)
Adults (N = 435)' 85% 207 82(19%) 34 35
Children (N = 82)d 79% 29 4 (4%) 15 25
a Data taken from Ref. 48.
bAbbreviations used are: N, number of patients studied; NS, nephrotic syndrome; F/U, follow-up; CFR, chronic renal failure.
Adult, >15 years old at apparent onset.
dChildren, <15 years old at apparent onset.
DR. C. H. C0GGINs: For the past several years
we have been conducting a prospective cooperative
study on the effect of prednisone compared to pla-
cebo in adults with the idiopathic nephrotic syn-
drome [101. Patients were randomly allocated either
to a treatment or control group.
The patients in the group receiving prednisone
underwent therapy for 2 months during which they
received prednisone every second day. This was
followed by tapering of medication for approxi-
mately 1 month at the discretion of the individual
physician. All patients who remitted and then re-
lapsed again received additional treatment. Of the
group of 34 patients, however, only 5 patients re-
ceived more than one dose. The treated group had
significantly more remissions, less proteinuria, and,
of the greatest import, better maintenance of creati-
nine clearance during the follow-up period. We
were surprised to find an observable difference and
tried to find some way in which the groups were not
comparable, or whether the therapeutic group ini-
tially contained patients with a better prognosis. We
compared a large number of clinical, laboratory,
and histologic characteristics of the patients in both
groups and found no correlation between the prog-
nosis and these characteristics. Further, we found
no selection bias between the treatment and control
groups. There seems to be no other explanation for
the differences other than the prednisone therapy.
The duration of observation of both groups was the
same on the average, and each had an equal oppor-
tunity to develop problems. It may be a bit surpris-
ing that some of the control patients developed ren-
al failure so quickly.
DR. J. S. CAMERON: Yes, I was going to ask you
about that. The data (Fig. 2) reveal that it is very
unusual for patients to develop renal failure in less
than 4 years from apparent onset. The "stop point"
in your trial is a doubling of serum creatinine con-
centration, but I think you have 11 patients who are
in renal failure in the control group and only 1 in the
treatment group. Is that right?
DR. C. H. C0GGINs: Yes, the renal failure for 9 of
the 11 patients was rather severe. For 2 patients,
Table 3. The effect of treatment with corticosteroids on long-term follow-up in patients with membranous nephropathya
Group 1b
(N = 48)
Rx No Rx
Group IF(N = 103)
Rx No Rx
Group 111d
(N = 67)
Rx No Rx
Group Jye
(N = 26)
Rx No Rx
Dead 5 7 6 22 6 1 5 12
PersistentNS 5 2 12 11 15 5 0 0
Persistent proteinuria 8 9 24 ii 0 0 0 0
Remission 4 8 17 0 25 15 5 4
22 26 59 44 46 21 10 16
Follow-up 5.4 yr, mean 5.8 yr. mean ito 15 yr 0 to 23 yr
Duration of Rx 2 to 38 mo
(mean 7 mos)
6 wks to 39 mo NA NA
a Abbreviations used are: N, number of patients studied; Rx, administration of corticosteroids; NS, nephrotic syndrome; NA, data not
available.
b7 patients also received immunosuppressants, and analysis confined to NS since only nephrotic patients treated. Data taken from
Ref. 48.
16 patients also received immunosuppressants. Data taken from Ref. 50.
d24 patients also received immunosuppressants, and 7 of these did not receive corticosteroids. Data taken from Ref. 51.
All NS. Data taken from Ref. 52.
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Table 4. Results of controlled studies of immunosuppressant
drugs in patients with membranous nephropathy
Agent Duration Result
Corticosteroids 2 to 4 yr none
Azathioprine plus 2 none
Corticosteroids
Azathioprine 1 yr none
Cyclophosphamide 2 yr none
Chlorambucil 1 yr P & Ce,., sam&'
a Data taken from Ref. 53.
bp = proteinuria, Car creatinine clearance.
however, it shouldn't be called renal failure; their
serum creatinine concentrations simply doubled.
DR. J. S. CAMERON: Certainly from our own ex-
perience and the published literature, it is unusual
for one-third of the 35 control patients with nephrot-
ic syndrome to develop renal failure so soon.
DR. C. H. C0GGINs: Within about 2.5 years, one-
third of the group doubled their serum creatinine
concentrations. During the same time, two-thirds of
the patients did not raise their serum creatinine con-
centrations significantly. It sounds less dramatic
when stated that way and doesn't seem surprising.
Many patients in both groups are doing well as the
years go by with no sign at all of progression of their
renal disease. There is another point, which you
mentioned earlier, that we can confirm. Any patient
who has any kind of remission, even a partial remis-
sion defined as a reduction in proteinuria to below 2
g/day, has an excellent chance of maintaining GFR
in the future, confirming the findings of Idelson et al
[55].
DR. J. S. CAMERON: Yes. When the prognosis for
patients with proteinuria only is examined and com-
pared with that of patients with a full nephrotic syn-
drome, a consistent pattern appears with the single
exception of patients with SLE, where there is no
difference. Patients with mesangiocapillary, mem-
branous, and focal segmental sclerosing lesions,
and a nephrotic syndrome show almost identical
survival curves with about 30 to 40% having 10-year
survival. Those that were never nephrotic showed
about 90% survival at the same point. In other
words, simple clinical observation at the beginning
of the disease, the presence of swelling in the ankles
or more than 3 g of proteinuria, gives a useful prog-
nostic index although it is a gloomy one.
DR. J. T. HARRINGTON: Of those patients who
developed renal failure within 5 years, how many of
those patients unequivocally had normal renal func-
tion at 3 years as this patient does? It is my feeling
that if a patient survives 3 years and still has un-
equivocal normal function, the long-term prognosis
is very good [55]. Do you have any information on
this point?
DR. J. S. CAMERON: We do have data on this [48].
We have seen patients like the patient under dis-
cussion who maintain perfectly normal renal func-
tion for several years, but then very slowly develop
renal failure. I suspect, however, that you are right;
if a patient maintains normal renal function for 3 to
5 years, the prognosis could be considered general-
ly good but not invariably so.
DR. C. H. C0GGINs: One of the questions that we
asked of patients in our study was, When did edema
or proteinuria first develop? It is very soft" data
because often the patients don't know but will give
an answer. In looking at those answers, we found
no difference between the patients with persistence
of normal renal function and those in whom renal
function deteriorated rather rapidly.
DR. J. S. CAMERON: We have one patient who
has had proteinuria for 22 years generally short of
the nephrotic range [48]. There are several patients
in the literature with similar courses [56]. Certainly,
a few patients can persist for long periods with
membranous nephropathy without decline in renal
function but with persisting urine abnormalities
short of a nephrotic syndrome [57]. As we agreed
earlier, the presence of a nephrotic syndrome does
not necessarily indicate that the patient will do
poorly even if it persists for 4 or 5 years, but by and
large it marks the individual as a higher risk patient.
Looking at the survival curves in Fig. 2, it is an in-
dolent disease. The survival curves are in general
flat for the first few years, then bend over, which is
rather different from other forms of glomerulone-
phritis in which a mortality is seen in the first few
years.
DR. J. J. COHEN: The hypothesis that glomerular
disease develops because of the in situ formation of
immune complexes is a very intriguing one. If true,
would such a pathogenesis suggest to you a dil-
ferent therapeutic strategy from that presently
used?
DR. J. S. CAMERON: It might at the theoretical
level, but I don't think at the practical level as yet.
If we believe that the generation of immune com-
plexes in the circulation is the crucial event with
both the antibody and the antigen in solution, then
one can examine a number of things, including the
quantity of antibody or the avidity with which the
antibody combines with the antigen, and try to
modify these with therapeutic agents. If combina-
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tion takes place on a surface, however, in this case
the outside of the glomerular basement membrane,
then the nature of the combination may be very dif-
ferent. We already know, for example, that we can
do things in a tube with immune reactants in solu-
tion which, probably for reasons of steric hin-
drance, can't be done if some of the reactants are
fixed to the wall of the tube.
Instead of asking how complexes get into the
sites they do, in or on the capillary wall, we must
now ask how we might influence the access of free
antigen and free antibody to the site of reaction. Re-
cently, the influence of charge on the access of im-
mune materials and events that affect the charged
molecules within the glomerular capillary wall have
been explored. For example, aminonucleoside
nephrosis induced in the kidney denies access of
circulating immune complexes to the capillary wall
[58], whereas several other manipulations permit
access of the complexes.
I think the real implication for therapy is that any-
one who thinks about the therapy of established gb-
merulonephritis in simplistic terms is in difficulty.
Certainly, the old idea of using immunosuppres-
sants because gbomerulonephritis was supposed
to be a disease of hyperimmunity seems laughable
now. The new idea that we might simply activate
the T cells" with something like levamisole and
thus improve things is equally naive. Not only at
the level of cellular control, but even at the level
of local assembly of complexes, it is probably very
complicated. The in situ formation of complexes
also implies that the material in the circulation may
not tell us a thing about what is going on in the
kidney; it might even mislead us.
DR. J. DONOHOE (University Hospital, Boston):
Could I ask you about the comment that you made
concerning the pathogenesis of membranous ne-
phropathy? I think you said that it is unusual for
membranous nephropathy to recur in a transplant
patient.
DR. J. S. CAMERON: Yes. There are several de
novo cases in patients who undoubtedly had prob-
lems other than nephritis as a cause of renal failure
[59, 601, but there are only two patients so far
whose courses are reasonably well documented in
whom membranous nephropathy recurred follow-
ing renal transplantation [61, 62].
DR. J. D0N0H0E: Don't those cases strengthen
the argument in favor of circulating immune com-
plexes rather than in situ formation?
DR. J. S. CAMERON: I suspect that both mecha-
nisms—deposition of circulating immune com-
plexes and in situ complex formation—operate in
several types of glomerulonephritis, but possibly
the balance is in favor of in situ immune complex
formation in membranous nephropathy. Unpub-
lished work by Border and Glassock unequivocally
demonstrates circulating immune complexes in
Heymann nephritis of rats, the same disease in
which some others have shown in situ immune com-
plex formation, and I am sure that both are right.
There is in this model for the first time good evi-
dence for the operation of both mechanisms. It is
almost certainly true, although the evidence is less
clear, that both mechanisms operate in acute serum
sickness nephritis in rabbits. I suspect that it is a
question of predominance of one mechanism or the
other in some conditions. One would therefore ex-
pect that the minority of patients with membranous
nephropathy and large amounts of soluble immune
complexes in their circulation might have an aggres-
sive recurrence of the disorder in the graft.
DR. J. J. COHEN: It has recently been suggested
that complement receptors for C3b on the glomeru-
lar capillary wall play a role in some forms of im-
mune complex deposition. What do you think about
this suggestion?
DR. J. S. CAMERON: It may be important in hu-
man renal disease, but of course we know that rats
and many other animals who do not have glomeru-
lar C3b receptors can develop membranous ne-
phropathy and other forms of glomerulonephritis
that closely resemble the human disease. So, while
the possession in humans and a few closely related
primates of the C3b receptors (in the interstitium
incidentally as well as in the glomerulus) may have
an influence on the initiation and progression of dis-
ease, I can't believe it is a dominant mechansim. In
fact, human beings are a little resistant to the induc-
tion of nephritis compared with the incidence of
nephritis found in dogs, rats and mice; we are a rela-
tively nephritis-resistant rather than nephritis-prone
species. The presence of C3b receptors could relate
to this, but it should work exactly the other way
around. C3b receptors should allow the more avid
fixation of complement-fixing immune complexes in
the kidney.
With membranous nephropathy, it is interesting
that the C3b receptors are believed to be on the epi-
thelial cells of the glomeruli, and of course in mem-
branous nephropathy the immune deposits are sub-
epithelial. We do know also that these C3b recep-
tors may become undetectable and then return in
diseases that are exclusively subendothelial, such
as mesangiocapillary glomerulonephritis during
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complement fixation. I am inclined to think that at
the moment C3b receptors are a very nice phenom-
enon in search of a relation to something clinically
important!
DR. D. BERNARD (University Hospital, Boston):
Dr. Cameron, you mentioned that in your experi-
ence the drug-induced varieties of membranous ne-
phropathy will invariably fade away, perhaps over a
period of years. Recently, we had a patient who was
treated with gold therapy and subsequently devel-
oped severe nephrotic syndrome. After some 9
months, the disease persists despite some steroid
therapy. Would you give this patient a good progno-
sis?
DR. J. S. CAMERON: I think I would. Clearly,
there is the possibility of a secondary mechanism,
such as autologous antibody to immune complexes
formed in situ or deposited in the glomerulus. This
may happen in malarial nephropathy, for example.
There is also evidence in the literature suggesting
that not all cases of penicillamine-induced nephrop-
athy remit [631. The problem is that the patients
may not have been followed long enough. I think
the best report is by Gartner et al [64]. They fol-
lowed-up 31 patients with penicillamine-induced ne-
phropathy for more than 2 years and they found that
all patients got better after 2 years although many of
them had been fully nephrotic even after 1 year
(Nield, personal communication). What might still
be causing the nephrotic syndrome at 1 year is fasci-
nating. When you imply that this patient hasn't im-
proved, you have not yet waited for 24 months
when many patients finally remit.
Reprint requests to Dr. J. Stewart Cameron, Guy's Hospital
London Bridge SEI 9RT England.
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